Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
Stocks in this Quantisnow insightHealth Care
Historical context for AAPG
Across the 25 sessions after earlier AAPG headlines, the stock closed higher 8 times and lower 15 times, with a median move of 2.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AAPG | SPY |
|---|---|---|---|
| Jun 15, 2026 | Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress | -1.5% | +1.8% |
| Jun 10, 2026 | B. Riley Securities initiated coverage on Ascentage Pharma with a new price target | +0.0% | -1.6% |
| Jun 1, 2026 | Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026and 2 other headlines that session | -4.6% | +0.3% |
| May 22, 2026 | Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 | +1.7% | +0.4% |
| May 13, 2026 | Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress | +1.0% | +0.6% |
| May 12, 2026 | Ascentage Pharma to Participate in Three Upcoming Investor Conferences | -2.3% | -0.2% |
Quantisnow market dataNASDAQ
AAPG
Ascentage Pharma Group International
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2025
Get push alerts for AAPG
Full AAPG profile on Quantisnow Follow AAPG and get a push notification the moment its next story breaks.